Vitamin D and Androgen Receptor-Targeted Therapy for Triple-Negative Breast Cancer
April 2016
in “
Breast Cancer Research and Treatment
”
TLDR Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.
The study investigated the potential of targeting vitamin D receptor (VDR) and androgen receptor (AR) in treating triple-negative breast cancer (TNBC), finding that approximately two-thirds of TNBCs expressed these receptors. Researchers tested 15 breast cancer cell lines and found that VDR and AR agonists inhibited cell viability, induced cell cycle arrest, and apoptosis, with enhanced effects when combined with chemotherapy. AR antagonists inhibited proliferation in an AR-independent manner. The study concluded that AR/VDR-targeted therapy could effectively inhibit TNBC through multiple mechanisms and could be combined with chemotherapy for enhanced efficacy, suggesting a promising therapeutic strategy for TNBC.
